Does High Plasma Immunoglobulin E in COPD Predict Exacerbation, Mortality Risk?
Could the level of plasma immunoglobulin E in patients with COPD serve as a potential biomarker for predicting future exacerbation risk and mortality?
Could the level of plasma immunoglobulin E in patients with COPD serve as a potential biomarker for predicting future exacerbation risk and mortality?
Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions.
Does home oxygen — either nocturnal oxygen therapy or LTOT — make a difference in the 3-year survival of patients with COPD and moderate hypoxemia?
How do individuals with undiagnosed asthma and COPD manifest these conditions over time, and how do these undiagnosed conditions affect quality of life?
Researchers assessed the occurrence and associated outcomes of frequent productive cough among patients with chronic obstructive lung disease and asthma.
In COPD, how does using single-inhaler triple therapy instead of multiple-inhaler triple therapy affect health care costs, mortality, and treatment adherence?
How does pulmonary rehabilitation of patients after COPD-related hospitalizations affect the overall cost of care and quality-adjusted life expectancy?
Can preventing gut permeability via multistrain probiotics prevent the muscle weakness and atrophy that often develops in older patients with COPD?
Does having an ongoing relationship with a health care provider — ie, relational continuity — affect outcomes in patients with asthma and COPD?
Which therapy more effectively prevents COPD exacerbations: dual bronchodilation with a long-acting beta agonist and a long-acting antimuscarinic agent, or LABA/ICS?